Ascorbic Acid for Anemia Management in Hemodialysis Patients: A Systematic Review and Meta-analysis

American Journal of Kidney Diseases

Volumn 54, Issue 6, 2009, Pages 1089-1097

  Deved, Vinay ^a,b   Poyah, Penelope ^c   James, Matthew T ^a,b   Tonelli, Marcello ^d   Manns, Braden J ^a,b   Walsh, Michael ^a,b   Hemmelgarn, Brenda R ^a,b  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c DALHOUSIE UNIVERSITY   (Canada)

^d UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Anemia; ascorbic acid; hemodialysis

Indexed keywords

ASCORBIC ACID; FERRITIN; HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN; TRANSFERRIN;

ANEMIA; ARTICLE; CELLULITIS; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DRUG USE; FERRITIN BLOOD LEVEL; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HEART INFARCTION; HEMODIALYSIS; HEMODIALYSIS PATIENT; HEMOGLOBIN BLOOD LEVEL; HEMOGLOBIN DETERMINATION; HUMAN; KIDNEY FAILURE; META ANALYSIS; MILIARY TUBERCULOSIS; OXALOSIS; SYSTEMATIC REVIEW; THERAPY EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; ANEMIA; ASCORBIC ACID; DOSE-RESPONSE RELATIONSHIP, DRUG; HEMOGLOBINS; HUMANS; KIDNEY FAILURE, CHRONIC; MIDDLE AGED; RENAL DIALYSIS; TREATMENT OUTCOME;

EID: 70449658877     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2009.06.040     Document Type: Article

References (42)

1. Sunder-Plassmann G., and Horl W.H. Erythropoietin and iron. Clin Nephrol. 47 3 (1997) 141-157
2. Locatelli F., Aljama P., Barany P., et al. Revised European Best Practice Guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant. 19 suppl 2 (2004) S1-S47
3. Winearls C.G., Oliver D.O., Pippard M.J., Reid C., Downing M.R., and Cotes P.M. Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis. Lancet 2 8517 (1986) 1175-1178
4. Eschbach J.W., Abdulhadi M.H., Browne J.K., et al. Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial. Ann Intern Med. 111 12 (1989) 992-1000
5. Tarng D.C., Huang T.P., and Doong T.I. Improvement of nutritional status in patients receiving maintenance hemodialysis after correction of renal anemia with recombinant human erythropoietin. Nephron. 78 3 (1998) 253-259
6. Foley R.N., Parfrey P.S., Morgan J., et al. Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy. Kidney Int. 58 3 (2000) 1325-1335
7. Jacobs C., Frei D., and Perkins A.C. Results of the European Survey on Anaemia Management 2003 (ESAM 2003): current status of anaemia management in dialysis patients, factors affecting epoetin dosage and changes in anaemia management over the last 5 years. Nephrol Dial Transplant. 20 suppl 3 (2005) S3-S24
8. Tarng D.C., Huang T.P., Chen T.W., and Yang W.C. Erythropoietin hyporesponsiveness: from iron deficiency to iron overload. Kidney Int. 55 suppl 69 (1999) S107-S118
9. National Kidney Foundation. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. Am J Kidney Dis. 47 suppl 3 (2006) S1-S145
10. Bridges K.R., and Hoffman K.E. The effects of ascorbic acid on the intracellular metabolism of iron and ferritin. J Biol Chem. 261 30 (1986) 14273-14277
11. Goldberg A. The enzymic formation of haem by the incorporation of iron into protoporphyrin; importance of ascorbic acid, ergothioneine and glutathione. Br J Haematol. 5 (1959) 150-157
12. Gastaldello K., Vereerstraeten A., Nzame-Nze T., Vanherweghem J.L., and Tielemans C. Resistance to erythropoietin in iron-overloaded haemodialysis patients can be overcome by ascorbic acid administration. Nephrol Dial Transplant. 10 suppl 6 (1995) S44-S47
13. Tarng D.C., and Huang T.P. A parallel, comparative study of intravenous iron versus intravenous ascorbic acid for erythropoietin-hyporesponsive anaemia in haemodialysis patients with iron overload. Nephrol Dial Transplant. 13 11 (1998) 2867-2872
14. Wyndham R., and Sapir D.G. Effects of vitamin C on anemia and iron metabolism in patients on maintenance haemodialysis. Aust N Z J Med. 10 (1980) 488
15. Lin C.L., Hsu P.Y., Yang H.Y., and Huang C.C. Low dose intravenous ascorbic acid for erythropoietin-hyporesponsive anemia in diabetic hemodialysis patients with iron overload. Ren Fail. 25 3 (2003) 445-453
16. Canavese C., Petrarulo M., Massarenti P., et al. Long-term, low-dose, intravenous vitamin C leads to plasma calcium oxalate supersaturation in hemodialysis patients. Am J Kidney Dis. 45 3 (2005) 540-549
17. McConnell K.N., Rolton H.A., Modi K.S., and Macdougall A.I. Plasma oxalate in patients with chronic renal failure receiving continuous ambulatory peritoneal dialysis or hemodialysis. Am J Kidney Dis. 18 4 (1991) 441-445
18. Costello J.F., Sadovnic M.J., and Cottington E.M. Plasma oxalate levels rise in hemodialysis patients despite increased oxalate removal. J Am Soc Nephrol. 1 12 (1991) 1289-1298
19. Moher D., Cook D.J., Eastwood S., Olkin I., Rennie D., and Stroup D.F. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Lancet 354 9193 (1999) 1896-1900
20. Weatherall M.S., and Sherry K.M. An evaluation of the Spuncrit infra-red analyser for measurement of haematocrit. Clin Lab Haematol. 19 3 (1997) 183-186
21. Higgins J.P.T., Deeks J.J., Altman D.G., and Cochrane Statistical Methods Group. Special topics in statistics; Chapter 16. Version 5.0.1 [updated September 2008]. In: Higgins J.P.T., and Green S. (Eds). Cochrane Handbook for Systematic Reviews of Interventions (2008), The Cochrane Collaboration. http://www.cochrane-handbook.org Available from www.cochrane-handbook.org. Accessed September 1, 2009
22. Wiebe N., Vandermeer B., Platt R.W., Klassen T.P., Moher D., and Barrowman N.J. A systematic review identifies a lack of standardization in methods for handling missing variance data. J Clin Epidemiol. 59 4 (2006) 342-353
23. Thiessen P.H., Barrowman N., and Garg A.X. Imputing variance estimates do not alter the conclusions of a meta-analysis with continuous outcomes: a case study of changes in renal function after living kidney donation. J Clin Epidemiol. 60 3 (2007) 228-240
24. Elbourne D.R., Altman D.G., Higgins J.P., Curtin F., Worthington H.V., and Vail A. Meta-analyses involving cross-over trials: methodological issues. Int J Epidemiol. 31 1 (2002) 140-149
25. Egger M., Smith G.D., and Altman D.G. Systematic Reviews in Health Care: Meta-analysis in Context. 2nd ed. (2001), BMJ Publishing Group, London
26. Sezer S., Ozdemir F.N., Yakupoglu U., Arat Z., Turan M., and Haberal M. Intravenous ascorbic acid administration for erythropoietin-hyporesponsive anemia in iron loaded hemodialysis patients. Artif Organs 26 4 (2002) 366-370
27. Deira J., Diego J., Martinez R., et al. Comparative study of intravenous ascorbic acid versus low-dose desferroxamine in patients on hemodialysis with hyperferritinemia. J Nephrol. 16 5 (2003) 703-709
28. Chan D., Irish A., and Dogra G. Efficacy and safety of oral versus intravenous ascorbic acid for anaemia in haemodialysis patients. Nephrology 10 4 (2005) 336-340
29. Attallah N., Osman-Malik Y., Frinak S., and Besarab A. Effect of intravenous ascorbic acid in hemodialysis patients with EPO-hyporesponsive anemia and hyperferritinemia. Am J Kidney Dis. 47 4 (2006) 644-654
30. Giancaspro V., Nuzziello M., Pallotta G., Sacchetti A., and Petrarulo F. Intravenous ascorbic acid in hemodialysis patients with functional iron deficiency: a clinical trial. J Nephrol. 13 6 (2000) 444-449
31. Keven K., Kutlay S., Nergizoglu G., and Erturk S. Randomized, crossover study of the effect of vitamin C on EPO response in hemodialysis patients. Am J Kidney Dis. 41 6 (2003) 1233-1239
32. Coyne D.W., Kapoian T., Suki W., et al. Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study. J Am Soc Nephrol. 18 3 (2007) 975-984
33. Kapoian T., O'Mara N.B., Singh A.K., et al. Ferric gluconate reduces epoetin requirements in hemodialysis patients with elevated ferritin. J Am Soc Nephrol. 19 2 (2008) 372-379
34. Ali M., Fayemi A.O., Rigolosi R., Frascino J., Marsden T., and Malcolm D. Hemosiderosis in hemodialysis patients. An autopsy study of 50 cases. JAMA 244 4 (1980) 343-345
35. Boelaert J.R., Daneels R.F., Schurgers M.L., Matthys E.G., Gordts B.Z., and Van Landuyt H.W. Iron overload in haemodialysis patients increases the risk of bacteraemia: a prospective study. Nephrol Dial Transplant. 5 2 (1990) 130-134
36. Phrommintikul A., Haas S.J., Elsik M., and Krum H. Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. Lancet 369 9559 (2007) 381-388
37. Lipschitz D.A., Bothwell T.H., Seftel H.C., Wapnick A.A., and Charlton R.W. The role of ascorbic acid in the metabolism of storage iron. Br J Haematol. 20 2 (1971) 155-163
38. Tarng D.C., Wei Y.H., Huang T.P., Kuo B.I., and Yang W.C. Intravenous ascorbic acid as an adjuvant therapy for recombinant erythropoietin in hemodialysis patients with hyperferritinemia. Kidney Int. 55 6 (1999) 2477-2486
39. Canavese C., Petrarulo M., Massarenti P., et al. Long-term, low-dose, intravenous vitamin C leads to plasma calcium oxalate supersaturation in hemodialysis patients. Am J Kidney Dis. 45 3 (2005) 540-549
40. Pru C., Eaton J., and Kjellstrand C. Vitamin C intoxication and hyperoxalemia in chronic hemodialysis patients. Nephron 39 2 (1985) 112-116
41. Morgan S.H., Maher E.R., Purkiss P., Watts R.W., and Curtis J.R. Oxalate metabolism in end-stage renal disease: the effect of ascorbic acid and pyridoxine. Nephrol Dial Transplant. 3 1 (1988) 28-32
42. Padayatty S.J., Sun H., Wang Y., et al. Vitamin C pharmacokinetics: implications for oral and intravenous use. Ann Intern Med. 140 7 (2004) 533-537